Poteligeo for the Treatment of Mycosis Fungoides and Sezary Syndrome
Poteligeo® (mogamulizumab-kpkc) is a monoclonal antibody (mAb) indicated for the treatment of mycosis fungoides and Sézary syndrome in adults.
Trending:
Poteligeo® (mogamulizumab-kpkc) is a monoclonal antibody (mAb) indicated for the treatment of mycosis fungoides and Sézary syndrome in adults.
No articles found matching your query